Provider Briefing: Xifaxan Access in 2026

Rifaximin (Xifaxan) has become a cornerstone of therapy for hepatic encephalopathy prophylaxis and IBS-D management. But increasingly, the prescribing conversation doesn't end at the Rx pad — it continues when patients call back to report they can't fill their prescriptions.

This briefing covers the current state of Xifaxan availability, the factors driving access challenges, and practical steps you can take to help your patients maintain continuity of care.

Current Supply Status

As of February 2026, Xifaxan (Rifaximin) is not listed on the FDA Drug Shortage Database. There is no formal manufacturing disruption reported by Salix Pharmaceuticals (Bausch Health), the sole manufacturer.

However, the clinical reality diverges from the regulatory picture. Many patients — particularly those in rural areas, those using smaller retail pharmacies, and those without robust insurance coverage — report significant difficulty obtaining Rifaximin on a consistent basis.

This is not a traditional supply shortage. It is a market-access shortage driven by cost, single-source manufacturing, and payer restrictions.

Timeline: How We Got Here

• 2004: FDA approves Rifaximin 200 mg (Xifaxan) for travelers' diarrhea
• 2010: FDA approves Xifaxan 550 mg for reduction of overt HE recurrence
• 2015: FDA approves Xifaxan 550 mg for IBS-D
• 2017–2023: Off-label prescribing for SIBO expands dramatically
• 2024–2026: Rising demand, persistently high pricing (~$2,000/month), and no generic entry continue to constrain patient access

Generic Rifaximin remains unavailable. Current patent and exclusivity protections for Xifaxan are projected to extend through 2028–2029.

Prescribing Implications

The access challenges around Xifaxan have direct clinical implications:

Hepatic Encephalopathy

For patients on maintenance Rifaximin 550 mg BID for HE prophylaxis, interruptions in therapy can precipitate overt HE episodes — with potential for hospitalization, cognitive decline, and caregiver burden. The AASLD guidelines recommend Rifaximin as add-on to Lactulose after the first episode of overt HE, making consistent access clinically important.

If a patient cannot obtain Rifaximin, ensure Lactulose dosing is optimized (titrate to 2–3 soft stools daily). Neomycin (500–1,000 mg Q6–8h) is a secondary alternative, though long-term use carries nephrotoxicity and ototoxicity risks.

IBS-D

Rifaximin for IBS-D is prescribed as a 14-day course (550 mg TID) with the option to repeat up to two additional times if symptoms recur. This episodic dosing pattern means patients may face the access challenge each time they need a new course.

Alternative agents include:

• Eluxadoline (Viberzi) 75–100 mg BID — contraindicated in patients without a gallbladder or with a history of pancreatitis
• Alosetron (Lotronsa) — restricted to women with severe IBS-D via the Prescribing Program for Lotronsa
• Low-dose tricyclic antidepressants (e.g., Amitriptyline 10–25 mg QHS) for visceral pain modulation
• Loperamide for symptomatic management

SIBO

For off-label SIBO treatment, access barriers are amplified because many payers will not cover Rifaximin for non-FDA-approved indications. Alternatives include Metronidazole, Ciprofloxacin, or Amoxicillin-clavulanate, though evidence supporting these is weaker than for Rifaximin.

Availability Picture: Why Patients Can't Fill

When patients report they "can't find" Xifaxan, the root causes typically fall into four categories:

1. Pharmacy stocking decisions: At $1,600–$2,200 per fill, many retail pharmacies don't stock Rifaximin routinely. They order on demand, which adds 1–3 business days.
2. Prior authorization delays: Most commercial plans and Medicare Part D formularies require PA for Xifaxan. Processing times vary from 24 hours to 2+ weeks, depending on the payer.
3. Step therapy requirements: For HE, some plans require documented Lactulose trial. For IBS-D, payers may require failure of first-line agents.
4. Cost-driven abandonment: Even with insurance, copays on specialty-tier medications can exceed $200–$500/month, leading patients to abandon prescriptions at the pharmacy counter.

Cost and Access Landscape

Understanding the financial barriers helps in counseling patients:

• Cash price: $1,600–$2,200/month (HE); $1,400–$1,800/course (IBS-D)
• Manufacturer copay card: Eligible commercially insured patients may pay $0. Not valid for government insurance (Medicare, Medicaid, VA, TRICARE).
• Bausch Health Patient Assistance Program: Provides free medication to qualifying uninsured/underinsured patients.
• PAN Foundation: Copay assistance for patients with financial need.

For patients on Medicare or Medicaid who cannot afford out-of-pocket costs, the Bausch Health PAP or the PAN Foundation are the most viable options. Your staff can initiate applications on behalf of patients.

Tools and Resources for Your Practice

Medfinder for Providers

Medfinder offers a real-time pharmacy availability tool that your practice can use to help patients locate pharmacies with Xifaxan in stock. Instead of asking patients to call around, direct them to medfinder.com/providers or use it during the office visit to identify a pharmacy before the patient leaves.

Prior Authorization Support

Proactively submitting prior authorization with the initial prescription can reduce delays significantly. Key documentation to include:

• Diagnosis with ICD-10 code (K72.x for HE, K58.0 for IBS-D)
• Prior treatments trialed and failed (for step therapy)
• Clinical rationale for Rifaximin specifically
• Specialist recommendation letter if prescribed by GI/hepatology

Sample Management

If your practice receives Xifaxan samples from Salix representatives, consider maintaining a small stock for bridge therapy while patients navigate PA or pharmacy ordering delays.

Looking Ahead

The Xifaxan access situation is unlikely to change meaningfully until generic Rifaximin enters the market, currently projected for 2028–2029. Until then, providers play a critical role in:

• Setting realistic expectations with patients about potential access delays
• Proactively managing prior authorizations
• Connecting patients with savings programs
• Having clear backup plans for therapy interruptions

For a patient-facing overview of this topic, see our post: Xifaxan shortage update for patients. For guidance on helping patients navigate cost barriers, see: How to help patients save money on Xifaxan.

Final Thoughts

Xifaxan remains clinically irreplaceable for many patients with hepatic encephalopathy and IBS-D. The access challenges are real, but they're navigable with proactive planning, appropriate use of savings programs, and tools like Medfinder that make the logistics of finding this medication less burdensome for both providers and patients.